Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)
Authors
Keywords
-
Journal
MODERN PATHOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-08-06
DOI
10.1038/s41379-020-0644-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial
- (2019) Robert Haddad et al. CANCER
- “Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy
- (2019) Emina Torlakovic et al. MODERN PATHOLOGY
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma
- (2018) Anjelica Hodgson et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non–Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs
- (2018) Enrico Munari et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective
- (2018) D.N. Ionescu et al. Current Oncology
- Importance of choice of materials and methods in PD-L1 and TIL assessment in oropharyngeal squamous cell carcinoma
- (2018) Astrid De Meulenaere et al. HISTOPATHOLOGY
- Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
- (2018) Robert L. Ferris et al. ORAL ONCOLOGY
- Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
- (2018) M Oliva et al. ANNALS OF ONCOLOGY
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
- (2018) Ezra E W Cohen et al. LANCET
- Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
- (2017) Kevin J Harrington et al. LANCET ONCOLOGY
- FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum‐Containing Chemotherapy
- (2017) Erin Larkins et al. ONCOLOGIST
- A comparative study of PD-L1 diagnostic assays in squamous cell carcinoma of the head and neck (SCCHN)
- (2016) M.J. Ratcliffe et al. ANNALS OF ONCOLOGY
- Programmed Death Ligand-1 Immunohistochemistry— A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society
- (2016) Lynette M. Sholl et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- HPV-positive oropharyngeal squamous cell carcinoma is associated withTIMP3andCADM1promoter hypermethylation
- (2014) Pauline M. W. van Kempen et al. Cancer Medicine
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now